Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
- PMID: 15753463
- DOI: 10.1200/JCO.2005.01.172
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
Abstract
Purpose: To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance.
Methods: Specimen pairs from 39 patients were tissue arrayed and stained for ER, progesterone receptor (PgR), Bcl-2, c-ErbB2 (HER-2), and phosphorylated (p) p38 mitogen-activated protein kinase (MAPK), p-ERK1/2 MAPK, and p-Akt. Xenograft MCF-7 tumors before and after tamoxifen resistance were assessed for levels of p-p38.
Results: Pretreatment, there were strong correlations between ER, PgR, and Bcl-2, and an inverse correlation between ER and HER-2. These correlations were lost in the tamoxifen- resistant tumors and replaced by strong correlations between ER and p-p38 and p-ERK. ER expression was lost in 17% of resistant tumors. Three (11%) of the 26 tumors originally negative for HER-2 became amplified and/or overexpressed at resistance. All ER-positive tumors that overexpressed HER-2 originally or at resistance expressed high levels of p-p38. In the pretreatment and tamoxifen-resistant specimens, there were strong correlations between p-p38 and p-ERK. In the tamoxifen-resistant xenograft tumors, like the clinical samples, there was a striking increase in p-p38.
Conclusion: The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance.
Similar articles
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707. Cancer Res. 2008. PMID: 18245484
-
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046
-
Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916237 Review.
-
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.
Cited by
-
Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.Breast Cancer Res Treat. 2013 Jan;137(2):523-31. doi: 10.1007/s10549-012-2336-6. Epub 2012 Nov 27. Breast Cancer Res Treat. 2013. PMID: 23184079 Free PMC article.
-
Exploring new pathways in endocrine-resistant breast cancer.Explor Target Antitumor Ther. 2022;3(3):337-361. doi: 10.37349/etat.2022.00086. Epub 2022 Jun 20. Explor Target Antitumor Ther. 2022. PMID: 36045911 Free PMC article. Review.
-
Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.IET Syst Biol. 2018 Oct;12(5):226-232. doi: 10.1049/iet-syb.2017.0058. IET Syst Biol. 2018. PMID: 30259868 Free PMC article.
-
EGFR associated expression profiles vary with breast tumor subtype.BMC Genomics. 2007 Jul 31;8:258. doi: 10.1186/1471-2164-8-258. BMC Genomics. 2007. PMID: 17663798 Free PMC article.
-
Breast Cancer Treatment in the Era of Molecular Imaging.Breast Care (Basel). 2008;3(6):409-414. doi: 10.1159/000181160. Epub 2008 Dec 17. Breast Care (Basel). 2008. PMID: 21048912 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous